|
Rani Therapeutics Holdings, Inc. (RANI) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Rani Therapeutics Holdings, Inc. (RANI) Bundle
Streamline your analysis and improve precision with our (RANI) DCF Calculator! Utilizing real data from Rani Therapeutics and customizable assumptions, this tool empowers you to forecast, analyze, and evaluate Rani Therapeutics Holdings, Inc. like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0 | .5 | 2.7 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -52.81 | 488.1 | -100 | 0 | -13.2 | -13.2 | -13.2 | -13.2 | -13.2 |
| EBITDA | -26.0 | -16.0 | -52.1 | -60.9 | -65.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -2657.1 | -3453.46 | -1916.97 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .6 | .6 | .5 | 1.3 | .8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 57.61 | 127.49 | 18.29 | 100 | 100 | 75.18 | 75.18 | 75.18 | 75.18 | 75.18 |
| EBIT | -26.6 | -16.5 | -52.6 | -62.2 | -66.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -2714.71 | -3580.95 | -1935.26 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 16.5 | 73.1 | 117.5 | 98.5 | 48.5 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .3 | 1.7 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 25.54 | 372.29 | 0 | 100 | 100 | 65.11 | 65.11 | 65.11 | 65.11 | 65.11 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.000102145046 | 0 | 0 | 100 | 100 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | .2 | .5 | 1.1 | 1.5 | .6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 20.22 | 116.23 | 39.75 | 100 | 100 | 71.99 | 71.99 | 71.99 | 71.99 | 71.99 |
| Capital Expenditure | -1.6 | -1.2 | -.5 | -1.6 | -1.2 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -161.49 | -259.74 | -18.62 | 100 | 100 | -43.72 | -43.72 | -43.72 | -43.72 | -43.72 |
| Tax Rate, % | 49.96 | 49.96 | 49.96 | 49.96 | 49.96 | 49.96 | 49.96 | 49.96 | 49.96 | 49.96 |
| EBITAT | -26.6 | -16.6 | -52.6 | -62.3 | -33.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -27.7 | -18.3 | -50.4 | -62.2 | -34.3 | -.6 | .0 | .0 | .0 | .0 |
| WACC, % | 10.16 | 10.16 | 10.16 | 10.16 | 6.49 | 9.43 | 9.43 | 9.43 | 9.43 | 9.43 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | 24 | |||||||||
| Equity Value | -25 | |||||||||
| Diluted Shares Outstanding, MM | 26 | |||||||||
| Equity Value Per Share | -0.97 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Rani Therapeutics Holdings, Inc. (RANI)’s financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life RANI Financials: Pre-filled historical and projected data for Rani Therapeutics Holdings, Inc. (RANI).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Rani’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Rani’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Rani Therapeutics Holdings, Inc.'s (RANI) pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator?
- Designed for Industry Experts: A sophisticated tool utilized by researchers, CFOs, and investment analysts.
- Comprehensive Data: Rani Therapeutics' historical and projected financials included for precise analysis.
- Flexible Scenario Analysis: Effortlessly model various forecasts and assumptions.
- Concise Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance simplifies the entire process.
Who Should Use This Product?
- Investors: Evaluate Rani Therapeutics' potential before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and validate financial forecasts.
- Startup Founders: Understand the valuation strategies of innovative biotech companies like Rani Therapeutics.
- Consultants: Create detailed valuation reports for clients in the healthcare sector.
- Students and Educators: Utilize real-world examples to practice and teach valuation concepts.
What the Template Contains
- Pre-Filled Data: Includes Rani Therapeutics Holdings, Inc.'s (RANI) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations tailored for Rani Therapeutics.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs specific to RANI.
- Key Financial Ratios: Analyze Rani Therapeutics' profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily edit revenue growth, margins, and tax rates relevant to RANI.
- Clear Dashboard: Charts and tables summarizing key valuation results for Rani Therapeutics Holdings, Inc. (RANI).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.